Chemometec A/S
CSE:CHEMM

Watchlist Manager
Chemometec A/S Logo
Chemometec A/S
CSE:CHEMM
Watchlist
Price: 352.2 DKK 4.57% Market Closed
Market Cap: kr6.1B

Chemometec A/S
Total Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Chemometec A/S
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Chemometec A/S
CSE:CHEMM
Total Equity
kr652.6m
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
N/A
G
Gubra A/S
CSE:GUBRA
Total Equity
kr1.1B
CAGR 3-Years
120%
CAGR 5-Years
70%
CAGR 10-Years
N/A
No Stocks Found

Chemometec A/S
Glance View

Chemometec A/S, a Danish firm founded in the late 1990s, has carved a niche in the specialized world of biotech instrumentation. The company is renowned for developing and manufacturing high-precision cell counting and analysis instruments used predominantly in the life sciences sector. Its flagship product, the NucleoCounter®, has gained significant traction in laboratories and production facilities worldwide. This product stands out due to its accuracy and ease of use in counting various types of cells, whether in research or pharmaceutical production settings. Unlike traditional methods, Chemometec’s technology enables researchers to save time and reduce error, which is invaluable for laboratories looking to enhance their workflow efficiencies. Revenue for Chemometec is primarily generated through the sale of its advanced instruments and associated consumables, along with providing expert services that support the integration and maintenance of these technologies. The company's business model capitalizes on the growing global demand for sophisticated biomedical research tools, as innovation in the drug development and biotechnology sectors accelerates. By continuously investing in R&D, Chemometec not only ensures its products remain cutting-edge but also expands its applicability across new areas in the life sciences field. The strategy of maintaining close relationships with its end-users ensures that as the scientific landscape evolves, Chemometec is well-positioned to adapt and grow.

CHEMM Intrinsic Value
LOCKED
Unlock

See Also

What is Chemometec A/S's Total Equity?
Total Equity
652.6m DKK

Based on the financial report for Dec 31, 2025, Chemometec A/S's Total Equity amounts to 652.6m DKK.

What is Chemometec A/S's Total Equity growth rate?
Total Equity CAGR 5Y
24%

Over the last year, the Total Equity growth was 9%. The average annual Total Equity growth rates for Chemometec A/S have been 13% over the past three years , 24% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett